Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive Breast Cancer Cells.

Tagliatti E, Gagliani MC, Bellese G, Salamat S, Crippa M, Sollazzo M, Abbona A, Paccagnella M, Arnaldi P, Rossi L, Petretto A, Rusmini P, Crippa V, Merlano MC, Garrone O, Porcelli AM, Matteoli M, Falletta P, Castagnola P, Cortese K

Open source

DOI: 10.1021/acsnanomed.6c00097
Published: 2026 Sep 9
Container: ACS nano medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1021/acsnanomed.6c00097,
  title = {Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive Breast Cancer Cells.},
  author = {Tagliatti E and Gagliani MC and Bellese G and Salamat S and Crippa M and Sollazzo M and Abbona A and Paccagnella M and Arnaldi P and Rossi L and Petretto A and Rusmini P and Crippa V and Merlano MC and Garrone O and Porcelli AM and Matteoli M and Falletta P and Castagnola P and Cortese K},
  year = {2026},
  journal = {ACS nano medicine},
  doi = {10.1021/acsnanomed.6c00097},
  url = {https://doi.org/10.1021/acsnanomed.6c00097}
}

RIS

TY  - JOUR
TI  - Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive Breast Cancer Cells.
AU  - Tagliatti E
AU  - Gagliani MC
AU  - Bellese G
AU  - Salamat S
AU  - Crippa M
AU  - Sollazzo M
AU  - Abbona A
AU  - Paccagnella M
AU  - Arnaldi P
AU  - Rossi L
AU  - Petretto A
AU  - Rusmini P
AU  - Crippa V
AU  - Merlano MC
AU  - Garrone O
AU  - Porcelli AM
AU  - Matteoli M
AU  - Falletta P
AU  - Castagnola P
AU  - Cortese K
PY  - 2026
JO  - ACS nano medicine
DO  - 10.1021/acsnanomed.6c00097
UR  - https://doi.org/10.1021/acsnanomed.6c00097
ER  -

APA

E, T., MC, G., G, B., S, S., M, C., M, S., A, A., M, P., P, A., L, R., A, P., P, R., V, C., MC, M., O, G., AM, P., M, M., P, F., P, C., & K, C. (2026). Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive Breast Cancer Cells.. ACS nano medicine. https://doi.org/10.1021/acsnanomed.6c00097

Source records

pubmed · retrieved 2026-09-26T08:20:56.102Z